Optimization of levosimendan before left ventricular assist device implantation in pediatric patients

Area of Science:

• Pediatric cardiology
• Cardiovascular surgery
• Pharmacology

Background:

• Left ventricular assist device (LVAD) implantation in pediatric patients is a complex procedure with significant challenges.
• Optimizing perioperative management is crucial for improving outcomes in this unique patient population.
• Levosimendan, a calcium sensitizer, has shown potential in adult cardiac surgery but its role in pediatric LVAD recipients is less defined.

Purpose of the Study:

• To evaluate the impact of preoperative levosimendan administration on postoperative outcomes in pediatric patients undergoing LVAD implantation.
• To assess the safety and efficacy of levosimendan in this specific cohort.
• To compare outcomes between patients receiving levosimendan and those receiving standard inotropic therapy.

Main Methods:

• Retrospective single-center study of pediatric patients (<18 years) undergoing LVAD implantation, excluding INTERMACS class 1.
• Patients were divided into two groups: Group A (n=14) received preoperative levosimendan plus standard inotropic therapy; Group B (n=17) received standard inotropic therapy alone.
• Primary outcomes included early right ventricular failure and in-hospital mortality; secondary outcomes assessed right ventricular assist, late right ventricular failure, and organ function.

Main Results:

• No significant differences were observed in early right ventricular failure, in-hospital mortality, or length of stay between the levosimendan and control groups.
• Rates of right ventricular assist and late right ventricular failure were comparable between groups.
• While both groups showed organ function improvements, the levosimendan group exhibited significantly greater reductions in liver enzymes (AST, ALT); no treatment-limiting side effects were noted.

Conclusions:

• Preoperative levosimendan administration is safe for pediatric LVAD candidates.
• Levosimendan demonstrated improved end-organ function, particularly liver function, in pediatric LVAD recipients.
• The study did not show levosimendan's superiority over standard inotropic therapy in preventing right ventricular failure or reducing mortality in this population.